Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $9.58 and traded as high as $10.03. Astellas Pharma shares last traded at $9.63, with a volume of 81,803 shares traded.
Astellas Pharma Stock Down 0.8%
The company has a 50-day moving average of $9.60 and a 200 day moving average of $9.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.13 and a quick ratio of 0.85.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.12. The business had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a return on equity of 16.55% and a net margin of 2.65%. Analysts anticipate that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
See Also
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
